Developing next generation immunomodulatory drugs and their combinations in multiple myeloma. 

Thakurta A, et al. Oncotarget. 2021;12(15):1555-1563.  

Targeting Ikaros and Aiolos: next-generation cereblon E3 ligase modulators in MM. 

Alvaro ME, et al. Eur J Haematol. 2026;116(6):697-708. 

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. 

Lonial S, et al. Lancet Haematol. 2022;9(11):e822-e832.  

EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. 

Lonial S, et al. Future Oncol. 2025;21(14):1761-1769. 

Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. 

Richardson PG, et al. N Engl J Med. 2023;389(11):1009-1022.  

Diagnosis and management of multiple myeloma: a review.

Cowan AJ, et al. JAMA. 2022;327(5):464-477.  

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. 

Rajkumar SV. Am J Hematol. 2022;97(8):1086-1107. 

Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group.

Palumbo A, et al. J Clin Oncol. 2015;33(26):2863-2869.  

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Dimopoulos, MA, et al. Lancet. 2026:S0140-6736(26)01088-3. Epub ahead of print. 

American Society of Clinical Oncology 2026 Annual Meeting Abstracts.

Controversies in Multiple Myeloma (COMy) 2026 11th World Congress E-Posters.

European Hematology Association Congress 2026